Journal
ONCOGENE
Volume 34, Issue 35, Pages 4547-4557Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2014.399
Keywords
-
Funding
- NIH [RO1CA127901, RO1CA131421]
- DOD PCRP Postdoctoral Fellowship [PC121837]
- Irma T Hirschl Career Scientist Award
Ask authors/readers for more resources
pRb and p53 are the two major tumor suppressors. Their inactivation is frequent when cancers develop and their reactivation is rationale of most cancer therapeutics. When pRb and p53 are genetically inactivated, cells irreparably lose the antitumor mechanisms afforded by them. Cancer genome studies document recurrent genetic inactivation of RB1 and TP53, and the inactivation becomes more frequent in more advanced cancers. These findings may explain why more advanced cancers are more likely to resist current therapies. Finding successful treatments for more advanced and multi-therapy-resistant cancers will depend on finding antitumor mechanisms that remain effective when pRb and p53 are genetically inactivated. Here, we review studies that have begun to make progress in this direction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available